BioSpace News Archive

- Strategic investment from single biotech-focused institutional investor - - Enables clinical development of both fadraciclib and CYC140 in hematological malignancies and solid tumors -

LGC Maine Standards 1 announces the release of VALIDATE ® Diabetes to meet the linearity and calibration verification needs of clinical laboratories running the Roche cobas ® platform. The product (Order No. 204RO), which includes the analytes, beta-hydroxybutyrate, C-peptide, Fructosamine, and Insulin, is formulate

PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, announced today that it has entered into a securities purchase agreement with a single healthcare-dedicated institutional investor providing for the purchase and sale of 10,688,043 shares of its common stock

-- State-of-the-Art Site Near Portland, Oregon Expected to More than Double Manufacturing Capacity, Increase Speed of Production and Enable Enhanced Product Offerings --

Neomorph, Inc. announced a $109 million Series A financing to advance a proprietary targeted protein degradation platform and specific programs. Deerfield Management Company established Neomorph earlier this year with scientific founders Phil Chamberlain, DPhil; Eric Fischer, PhD; Benjamin Ebert, MD, PhD; and Scott Armstrong, MD, PhD.

Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that its Anti-Coronavirus drug development program is unaffected by the recent discovery of a new strain of Coronavirus in Southern England.

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today congratulated ImmunityBio, Inc. (“ImmunityBio”) and NantKwest, Inc. (NASDAQ: NK) (“NantKwest”) on their proposed merger and announced plans to create a leading immunotherapy and cell therapy company.

Omniome, Inc., developer of an innovative DNA sequencing platform capable of delivering unsurpassed sequencing accuracy, announces the promotion of Kelly Perez to Chief Operating Officer.

Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will virtually present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 7:30 a.m. Eastern time.

CANbridge Pharmaceuticals Inc., a company developing and commercializing innovative drugs to treat rare diseases and targeted cancers, announced that it has appointed Justin Lu to the position of General Manager of China, responsible for setting up and operating commercial operations in China